|
US7655699B1
(en)
|
1992-04-22 |
2010-02-02 |
Eisai Inc. |
Compounds having selective activity for retinoid X receptors, and means for modulation of processes mediated by retinoid X receptors
|
|
GB9222253D0
(en)
*
|
1992-10-23 |
1992-12-09 |
Celltech Ltd |
Chemical compounds
|
|
GB9304919D0
(en)
*
|
1993-03-10 |
1993-04-28 |
Celltech Ltd |
Chemical compounds
|
|
GB9304920D0
(en)
*
|
1993-03-10 |
1993-04-28 |
Celltech Ltd |
Chemical compounds
|
|
EP0738268B1
(en)
*
|
1993-12-22 |
2004-03-03 |
Celltech R&D Limited |
Trisubstituted phenyl derivatives, processes for their preparation and their use as phosphodiesterase (type iv) inhibitors
|
|
US6245774B1
(en)
|
1994-06-21 |
2001-06-12 |
Celltech Therapeutics Limited |
Tri-substituted phenyl or pyridine derivatives
|
|
US6942980B1
(en)
*
|
1995-09-01 |
2005-09-13 |
Allergan, Inc. |
Methods of identifying compounds having nuclear receptor negative hormone and/or antagonist activities
|
|
US5958954A
(en)
*
|
1995-09-01 |
1999-09-28 |
Allergan Sales, Inc. |
Synthesis and use of retinoid compounds having negative hormone and/or antagonist activities
|
|
GB9523675D0
(en)
*
|
1995-11-20 |
1996-01-24 |
Celltech Therapeutics Ltd |
Chemical compounds
|
|
GB9526243D0
(en)
*
|
1995-12-21 |
1996-02-21 |
Celltech Therapeutics Ltd |
Chemical compounds
|
|
GB9526245D0
(en)
*
|
1995-12-21 |
1996-02-21 |
Celltech Therapeutics Ltd |
Chemical compounds
|
|
US5877207A
(en)
*
|
1996-03-11 |
1999-03-02 |
Allergan Sales, Inc. |
Synthesis and use of retinoid compounds having negative hormone and/or antagonist activities
|
|
JP3995716B2
(ja)
|
1996-03-18 |
2007-10-24 |
エーザイ・アール・アンド・ディー・マネジメント株式会社 |
縮合環含有カルボン酸誘導体
|
|
GB9608435D0
(en)
*
|
1996-04-24 |
1996-06-26 |
Celltech Therapeutics Ltd |
Chemical compounds
|
|
US5773594A
(en)
|
1996-06-21 |
1998-06-30 |
Allergan |
Alkyl or aryl substituted dihydronaphthalene derivatives having retinoid and/or retinoid antagonist-like biological activity
|
|
WO1997048672A2
(en)
*
|
1996-06-21 |
1997-12-24 |
Allergan Sales, Inc. |
Substituted tetrahydronaphthalene and dihydronaphthalene derivatives having retinoid and/or retinoid antagonist-like biological activity
|
|
US6555690B2
(en)
|
1996-06-21 |
2003-04-29 |
Allergan, Inc. |
Alkyl or aryl substituted dihydronaphthalene derivatives having retinoid and/or retinoid antagonist-like biological activity
|
|
GB9619284D0
(en)
*
|
1996-09-16 |
1996-10-30 |
Celltech Therapeutics Ltd |
Chemical compounds
|
|
GB9622363D0
(en)
*
|
1996-10-28 |
1997-01-08 |
Celltech Therapeutics Ltd |
Chemical compounds
|
|
GB9625184D0
(en)
*
|
1996-12-04 |
1997-01-22 |
Celltech Therapeutics Ltd |
Chemical compounds
|
|
JP2001507349A
(ja)
*
|
1996-12-23 |
2001-06-05 |
セルテック セラピューティックス リミテッド |
縮合多環式２−アミノピリミジン誘導体、それらの製造およびたんぱく質チロシンキナーゼ抑制因子としてのそれらの使用
|
|
US5760276A
(en)
*
|
1997-03-06 |
1998-06-02 |
Allergan |
Aryl-and heteroarylcyclohexenyl substituted alkenes having retinoid agonist, antagonist or inverse agonist type biological activity
|
|
AU6955898A
(en)
*
|
1997-04-11 |
1998-11-11 |
Bristol-Myers Squibb Company |
Retinoid antagonists and uses thereof
|
|
CA2307879C
(en)
*
|
1997-11-12 |
2009-12-22 |
F. Hoffmann-La Roche Ag |
Treatment of t-helper cell type 2 mediated immune diseases
|
|
WO2000018885A1
(en)
*
|
1998-09-29 |
2000-04-06 |
Gamida Cell Ltd. |
Methods of controlling proliferation and differentiation of stem and progenitor cells
|
|
US6048873A
(en)
*
|
1998-10-01 |
2000-04-11 |
Allergan Sales, Inc. |
Tetrahdroquinolin-2-one 6 or 7-yl, tetrahdroquinilin-2-thione 6 or 7-yl pentadienoic acid and related derivatives having retinoid-like biological activity
|
|
US6147224A
(en)
*
|
1998-10-01 |
2000-11-14 |
Allergan Sales, Inc. |
2,4-pentadienoic acid derivatives having selective activity for retinoid X (RXR) receptors
|
|
US6403638B1
(en)
|
1998-10-01 |
2002-06-11 |
Allergan Sales, Inc. |
2,4-pentadienoic acid derivatives having selective activity for retinoid X (RXR) receptors
|
|
CA2346687A1
(en)
*
|
1998-10-08 |
2000-04-13 |
Allergan Sales, Inc. |
Use of rar antagonists or inverse agonists as male anit-fertility agents
|
|
US6521641B1
(en)
*
|
1998-10-08 |
2003-02-18 |
Allergan, Inc. |
Male anti-fertility agents
|
|
EP1137940A4
(en)
*
|
1998-10-23 |
2004-06-02 |
Glaxo Group Ltd |
METHOD FOR IDENTIFYING LIGANDS OF NUCLEAR RECEPTORS
|
|
US6326397B1
(en)
|
1998-11-10 |
2001-12-04 |
Hoffman-La Roche Inc. |
Retinoid antagonists and use thereof
|
|
US6054623A
(en)
*
|
1998-12-18 |
2000-04-25 |
Alliedsignal Inc. |
Hydroxythiol grignard reaction synthesis
|
|
ES2221371T3
(es)
*
|
1999-03-08 |
2004-12-16 |
Basilea Pharmaceutica Ag |
Antagonistas retinoides y el uso de los mismos.
|
|
WO2000061233A2
(en)
*
|
1999-04-14 |
2000-10-19 |
Allergan Sales, Inc. |
Methods and compositions for the treatment and prevention of lung disease involving a specific rar-gamma agonist
|
|
AU4225500A
(en)
*
|
1999-04-14 |
2000-11-14 |
Allergan Sales, Inc. |
Methods and compositions for the treatment and prevention of lung disease
|
|
US6869959B1
(en)
|
1999-04-28 |
2005-03-22 |
Institute Of Medicinal Molecular Design Inc. |
Heterocyclic carboxylic acid derivatives
|
|
CA2375797A1
(en)
|
1999-06-11 |
2000-12-21 |
Allergan Sales, Inc. |
Organosilyl compounds having nuclear hormone receptor modulating activity
|
|
US6906057B1
(en)
|
1999-06-11 |
2005-06-14 |
Allergan, Inc. |
Methods for modulating FXR receptor activity
|
|
US6566372B1
(en)
*
|
1999-08-27 |
2003-05-20 |
Ligand Pharmaceuticals Incorporated |
Bicyclic androgen and progesterone receptor modulator compounds and methods
|
|
AU6941200A
(en)
|
1999-08-27 |
2001-03-26 |
Ligand Pharmaceuticals Incorporated |
8-substituted-6-trifluoromethyl-9-pyrido(3,2-g)quinoline compounds as androgen receptor modulators
|
|
CZ2002711A3
(cs)
|
1999-08-27 |
2003-11-12 |
Ligand Pharmaceuticals Incorporated |
Modulátory androgenních receptorů, způsoby jejich výroby a způsoby jejich použití
|
|
JP2003529545A
(ja)
*
|
1999-09-14 |
2003-10-07 |
リガンド・ファーマシューティカルズ・インコーポレイテッド |
改善された薬理学的プロファイルを有するｒｘｒモジュレーター
|
|
US6313168B1
(en)
|
1999-12-15 |
2001-11-06 |
Allergan Sales, Inc. |
Use of retinoid receptor antagonists in the treatment of cartilage and bone pathologies
|
|
US20030114482A1
(en)
*
|
1999-12-15 |
2003-06-19 |
Maurizio Pacifici |
Use of retinoid receptor antagonists or agonists in the treatment of cartilage and bone pathologies
|
|
WO2002022113A2
(en)
|
2000-09-13 |
2002-03-21 |
Bristol-Myers Squibb Company |
Retinoic acid receptor antagonists as promoters of angiogenesis
|
|
US20030003517A1
(en)
*
|
2001-03-22 |
2003-01-02 |
Klein Elliott S. |
Methods of detecting dissociated nuclear hormone receptor ligands
|
|
US20020193403A1
(en)
*
|
2001-05-03 |
2002-12-19 |
Allergan Sales, Inc. |
Methods of treating hyperlipidemia
|
|
HRP20031081A2
(en)
|
2001-05-29 |
2005-10-31 |
Schering Aktiengesellschaft |
Cdk inhibiting pyrimidines, production thereof and their use as medicaments
|
|
US7482366B2
(en)
|
2001-12-21 |
2009-01-27 |
X-Ceptor Therapeutics, Inc. |
Modulators of LXR
|
|
JP5082033B2
(ja)
|
2001-12-21 |
2012-11-28 |
エグゼリクシス パテント カンパニー エルエルシー |
Ｌｘｒのモジュレーター
|
|
IL152904A0
(en)
*
|
2002-01-24 |
2003-06-24 |
Gamida Cell Ltd |
Utilization of retinoid and vitamin d receptor antagonists for expansion of renewable stem cell populations
|
|
WO2003062404A1
(en)
|
2002-01-25 |
2003-07-31 |
Gamida-Cell Ltd. |
Methods of expanding stem and progenitor cells and expanded cell populations obtained thereby
|
|
EP1532273A4
(en)
*
|
2002-06-20 |
2009-11-18 |
Primera Biosystems Inc |
DEVICE FOR DETECTING AND QUANTIFYING POLYNUCLEOTIDES
|
|
WO2004014388A1
(en)
*
|
2002-08-13 |
2004-02-19 |
Warner-Lambert Company Llc |
6,6-fused heteroaryl derivatives as matrix metalloproteinase inhibitors
|
|
US7105566B2
(en)
*
|
2002-10-22 |
2006-09-12 |
Allergan, Inc. |
Methods of treatment during vascular procedures
|
|
FR2847255B1
(fr)
*
|
2002-11-18 |
2006-11-17 |
Galderma Res & Dev |
Nouveaux ligands antagonistes des recepteurs rars, leur procede de preparation et leur utilisation en medecine humaine ainsi qu'en cosmetique
|
|
CA2505286C
(en)
*
|
2002-11-18 |
2012-02-07 |
Galderma Research & Development, S.N.C. |
Novel ligands that are antagonists of rar receptors, process for preparing them and use thereof in human medicine and in cosmetics
|
|
US20050026950A1
(en)
*
|
2003-07-30 |
2005-02-03 |
Allergan, Inc. |
Methods of therapeutic treatment using retinoids to achieve consistent bioavailability
|
|
US20050026958A1
(en)
*
|
2003-07-30 |
2005-02-03 |
Allergan, Inc. |
Methods of therapeutic treatment using amounts of retinoid components
|
|
WO2005011668A1
(en)
*
|
2003-07-30 |
2005-02-10 |
Allergan, Inc. |
Methods of therapeutic treatment using amounts of retinoid components
|
|
US20050026949A1
(en)
*
|
2003-07-30 |
2005-02-03 |
Allergan, Inc. |
Methods of therapeutic treatment using amounts of retinoids without regard to body weight
|
|
US20060141049A1
(en)
*
|
2003-11-12 |
2006-06-29 |
Allergan, Inc. |
Triamcinolone compositions for intravitreal administration to treat ocular conditions
|
|
US20070224278A1
(en)
*
|
2003-11-12 |
2007-09-27 |
Lyons Robert T |
Low immunogenicity corticosteroid compositions
|
|
US20050101582A1
(en)
|
2003-11-12 |
2005-05-12 |
Allergan, Inc. |
Compositions and methods for treating a posterior segment of an eye
|
|
JP2007518719A
(ja)
*
|
2003-12-26 |
2007-07-12 |
アラーガン インコーポレイテッド |
ＲＡＲγレチノイド受容体アンタゴニスト活性を有する二置換カルコンオキシム
|
|
BRPI0506983A
(pt)
|
2004-01-20 |
2007-07-03 |
Allergan Inc |
composições para terapia localizada dos olhos, compreendendo preferencialmente acetonida de triancinolona e ácido hialurÈnico
|
|
US8425929B2
(en)
*
|
2004-04-30 |
2013-04-23 |
Allergan, Inc. |
Sustained release intraocular implants and methods for preventing retinal dysfunction
|
|
WO2005110374A1
(en)
*
|
2004-04-30 |
2005-11-24 |
Allergan, Inc. |
Intraocular drug delivery systems containing a therapeutic component, a cyclodextrin, and a polymeric component
|
|
US20070059336A1
(en)
*
|
2004-04-30 |
2007-03-15 |
Allergan, Inc. |
Anti-angiogenic sustained release intraocular implants and related methods
|
|
US8722097B2
(en)
|
2004-04-30 |
2014-05-13 |
Allergan, Inc. |
Oil-in-water method for making polymeric implants containing a hypotensive lipid
|
|
US20050244463A1
(en)
*
|
2004-04-30 |
2005-11-03 |
Allergan, Inc. |
Sustained release intraocular implants and methods for treating ocular vasculopathies
|
|
US7771742B2
(en)
|
2004-04-30 |
2010-08-10 |
Allergan, Inc. |
Sustained release intraocular implants containing tyrosine kinase inhibitors and related methods
|
|
US20050244465A1
(en)
*
|
2004-04-30 |
2005-11-03 |
Allergan, Inc. |
Drug delivery systems and methods for treatment of an eye
|
|
US8591885B2
(en)
*
|
2004-04-30 |
2013-11-26 |
Allergan, Inc. |
Carbonic anhydrase inhibitor sustained release intraocular drug delivery systems
|
|
US20050244462A1
(en)
*
|
2004-04-30 |
2005-11-03 |
Allergan, Inc. |
Devices and methods for treating a mammalian eye
|
|
US8455656B2
(en)
|
2004-04-30 |
2013-06-04 |
Allergan, Inc. |
Kinase inhibitors
|
|
US8147865B2
(en)
*
|
2004-04-30 |
2012-04-03 |
Allergan, Inc. |
Steroid-containing sustained release intraocular implants and related methods
|
|
US20050244461A1
(en)
*
|
2004-04-30 |
2005-11-03 |
Allergan, Inc. |
Controlled release drug delivery systems and methods for treatment of an eye
|
|
US9498457B2
(en)
|
2004-04-30 |
2016-11-22 |
Allergan, Inc. |
Hypotensive prostamide-containing biodegradable intraocular implants and related implants
|
|
US20050244466A1
(en)
*
|
2004-04-30 |
2005-11-03 |
Allergan, Inc. |
Photodynamic therapy in conjunction with intraocular implants
|
|
US20050244471A1
(en)
*
|
2004-04-30 |
2005-11-03 |
Allergan, Inc. |
Estradiol derivative and estratopone containing sustained release intraocular implants and related methods
|
|
US20050244478A1
(en)
*
|
2004-04-30 |
2005-11-03 |
Allergan, Inc. |
Anti-excititoxic sustained release intraocular implants and related methods
|
|
US20050244458A1
(en)
*
|
2004-04-30 |
2005-11-03 |
Allergan, Inc. |
Sustained release intraocular implants and methods for treating ocular neuropathies
|
|
WO2005107708A1
(en)
|
2004-04-30 |
2005-11-17 |
Allergan, Inc. |
Biodegradable intravitreal tyrosine kinase inhibitors implants
|
|
US7993634B2
(en)
*
|
2004-04-30 |
2011-08-09 |
Allergan, Inc. |
Oil-in-oil emulsified polymeric implants containing a hypotensive lipid and related methods
|
|
US8673341B2
(en)
|
2004-04-30 |
2014-03-18 |
Allergan, Inc. |
Intraocular pressure reduction with intracameral bimatoprost implants
|
|
US7799336B2
(en)
|
2004-04-30 |
2010-09-21 |
Allergan, Inc. |
Hypotensive lipid-containing biodegradable intraocular implants and related methods
|
|
US8119154B2
(en)
*
|
2004-04-30 |
2012-02-21 |
Allergan, Inc. |
Sustained release intraocular implants and related methods
|
|
US20060009498A1
(en)
*
|
2004-07-12 |
2006-01-12 |
Allergan, Inc. |
Ophthalmic compositions and methods for treating ophthalmic conditions
|
|
EP1621191A1
(en)
*
|
2004-07-29 |
2006-02-01 |
Werner Bollag |
Treatment of inflammatory diseases by RXR Antagonists
|
|
EP1799812A4
(en)
|
2004-09-16 |
2009-09-09 |
Gamida Cell Ltd |
EX VIVO CULTIVATION METHODS OF STEM CELLS AND PRECURSOR BY CO-CULTURE WITH MESENCHYMAL CELLS
|
|
WO2006043965A1
(en)
*
|
2004-10-14 |
2006-04-27 |
Allergan, Inc. |
Therapeutic ophthalmic compositions containing retinal friendly excipients and related methods
|
|
WO2007041398A2
(en)
|
2005-09-30 |
2007-04-12 |
Vitae Pharmaceuticals, Inc. |
Treatment of cancer with specific rxr agonists
|
|
US8846393B2
(en)
|
2005-11-29 |
2014-09-30 |
Gamida-Cell Ltd. |
Methods of improving stem cell homing and engraftment
|
|
TR201819157T4
(tr)
*
|
2006-05-16 |
2019-01-21 |
Io Therapeutics Llc |
Kemoterapi Ve Veya Radyasyon Terapisinin Yan Etkilerinin Tedavisinde Kullanıma Yönelik Rar Antagonisti Veya Ters Agonisti
|
|
US8969415B2
(en)
|
2006-12-01 |
2015-03-03 |
Allergan, Inc. |
Intraocular drug delivery systems
|
|
EP2120917B1
(en)
*
|
2007-02-28 |
2014-01-22 |
University Of Kentucky Research Foundation |
Method for alleviating side effects of retinoic acid therapy and/or improving efficacy without interfering with efficacy
|
|
US7911053B2
(en)
*
|
2007-04-19 |
2011-03-22 |
Marvell World Trade Ltd. |
Semiconductor packaging with internal wiring bus
|
|
US8082730B2
(en)
*
|
2008-05-20 |
2011-12-27 |
Caterpillar Inc. |
Engine system having particulate reduction device and method
|
|
KR101041281B1
(ko)
*
|
2009-05-18 |
2011-06-14 |
주식회사 니프코코리아 |
자동차의 에어벤트 다이얼
|
|
DK2498783T3
(en)
|
2009-11-09 |
2018-12-10 |
Allergan Inc |
COMPOSITIONS AND PROCEDURES FOR STIMULATING HAIR GROWTH
|
|
KR20140041669A
(ko)
|
2011-06-03 |
2014-04-04 |
알러간, 인코포레이티드 |
레티노이드 화합물의 피지샘으로의 표적화된 전달
|
|
US10653650B2
(en)
|
2011-12-13 |
2020-05-19 |
Io Therapeutics, Inc. |
Treatment of diseases by concurrently eliciting remyelination effects and immunomodulatory effects using selective RXR agonists
|
|
MX352727B
(es)
|
2011-12-13 |
2017-12-06 |
Dartmouth College |
Tratamiento de trastorno autoinmune al usar agonistas de rxr.
|
|
WO2013121426A1
(en)
|
2012-02-13 |
2013-08-22 |
Gamida-Cell Ltd. |
Culturing of mesenchymal stem cells
|
|
US9175266B2
(en)
|
2012-07-23 |
2015-11-03 |
Gamida Cell Ltd. |
Enhancement of natural killer (NK) cell proliferation and activity
|
|
US9567569B2
(en)
|
2012-07-23 |
2017-02-14 |
Gamida Cell Ltd. |
Methods of culturing and expanding mesenchymal stem cells
|
|
US20140094512A1
(en)
|
2012-10-02 |
2014-04-03 |
Nikolas Gunkel |
Method of modulating the degree of adipose tissue deposited intramuscularly
|
|
RU2641021C2
(ru)
|
2013-02-15 |
2018-01-17 |
Аллерган, Инк. |
Имплантат для пролонгированной доставки лекарственного средства
|
|
KR102651292B1
(ko)
|
2015-10-31 |
2024-03-25 |
아이오 테라퓨틱스, 인크. |
Rxr 아고니스트와 갑상선 호르몬의 조합을 사용한 신경계 질환의 치료
|
|
ES2898676T3
(es)
|
2015-11-25 |
2022-03-08 |
Io Therapeutics Inc |
Agonistas selectivos de rar-alfa resistentes a CYP26 en el tratamiento del cáncer
|
|
SG11201806628UA
(en)
|
2016-02-03 |
2018-09-27 |
Galderma Res & Dev |
New bi-aromatic propynyl compounds, pharmaceutical and cosmetic compositions containing them and uses thereof
|
|
DK3426302T3
(da)
|
2016-03-10 |
2023-02-27 |
Io Therapeutics Inc |
Behandling af autoimmunsygdomme med kombinationer af rxr-agonister og skjoldbruskkirtelhormoner
|
|
KR20180121983A
(ko)
|
2016-03-10 |
2018-11-09 |
아이오 테라퓨틱스, 인크. |
Rxr 작용제 및 갑상선 호르몬의 조합을 사용한 근육 질환의 치료
|
|
WO2017152725A1
(zh)
*
|
2016-03-11 |
2017-09-14 |
中国科学院上海有机化学研究所 |
一种视黄酸类化合物、其制备方法、中间体及应用
|
|
CN107176945B
(zh)
|
2016-03-11 |
2021-06-08 |
中国科学院上海有机化学研究所 |
一种视黄酸类化合物、其制备方法、中间体及应用
|
|
MX2018015352A
(es)
|
2016-06-10 |
2019-03-28 |
Io Therapeutics Inc |
Subtipos de receptores y compuestos retinoides y rexinoides de funcion selectiva combinados con moduladores inmunitarios para inmunoterapia contra el cancer.
|
|
CA3069676A1
(en)
|
2017-07-13 |
2019-01-17 |
Io Therapeutics, Inc. |
Immunomodulatory retinoid and rexinoid compounds in combination with immune modulators for cancer immunotherapy
|
|
WO2019046591A1
(en)
|
2017-08-31 |
2019-03-07 |
Io Therapeutics, Inc. |
SELECTIVE RAR AGONISTS IN ASSOCIATION WITH IMMUNE MODULATORS IN ANTICANCER IMMUNOTHERAPY
|
|
MX2020003223A
(es)
|
2017-09-20 |
2020-09-21 |
Io Therapeutics Inc |
Tratamiento de enfermedades con ésteres de agonistas de rxr selectivos.
|
|
US10966950B2
(en)
|
2019-06-11 |
2021-04-06 |
Io Therapeutics, Inc. |
Use of an RXR agonist in treating HER2+ cancers
|
|
KR20240119103A
(ko)
|
2021-12-07 |
2024-08-06 |
아이오 테라퓨틱스, 인크. |
Her2+ 암 치료에서의 rxr 작용제 및 탁산의 용도
|
|
MX2024006980A
(es)
|
2021-12-07 |
2024-07-19 |
Io Therapeutics Inc |
Uso de un agonista de rxr en el tratamiento de cáncer her2+ resistente a fármacos.
|